English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Dainippon Sumitomo Enters into a Licensing Agreement for a Treatment for Chronic Liver Disease

Mar. 29, 2011

Dainippon Sumitomo has entered into an exclusive licensing agreement with Intercept Pharmaceuticals for the development and commercialization of the latter's obeticholic acid, a first-in-class FXR agonist for the treatment of chronic liver diseases in China and Japan. Under the terms of the agreement, Intercept will receive an initial payment of $15 million from DSP and will be eligible to receive approximately $300 million in additional milestone payments associated with the successful development and commercialization of the drug.